ABIO insider filings
ARCA biopharma, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-08-30. Screen ABIO transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ABIO between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — ARCA biopharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-08-30 | 4 | Ma-Weaver Jacob | Other (J): 6,000 (derivative) · Other (J): 6,000 (derivative) · Other (J): 12,000 (derivative) | EDGAR |
| 2024-08-20 | 4 | JANUS HENDERSON GROUP PLC — 10% owner Janus Henderson Biotech Innovation Master Fund Ltd — 10% owner | Purchase (P): 5,390 @ $2.93 · Purchase (P): 428 @ $2.98 | EDGAR |
| 2024-07-26 | 4 | JANUS HENDERSON GROUP PLC — 10% owner Janus Henderson Biotech Innovation Master Fund Ltd — 10% owner | Purchase (P): 165,000 @ $3.20 · Purchase (P): 17,800 @ $3.18 · Purchase (P): 7,056 @ $3.16 · Purchase (P): 30,227 @ $3.05 | EDGAR |
| 2024-07-12 | 4 | JANUS HENDERSON GROUP PLC — 10% owner Janus Henderson Biotech Innovation Master Fund Ltd — 10% owner | Purchase (P): 166,042 @ $3.55 · Purchase (P): 23,326 @ $3.43 · Purchase (P): 5,000 @ $3.41 · Purchase (P): 29,892 @ $3.41 · Purchase (P): 17,600 @ $3.54 · Purchase (P): 16,917 @ $3.43 · +3 more | EDGAR |
| 2024-01-31 | 4 | Flynn James P — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Ma-Weaver Jacob — Director, 10% owner | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Woosley Raymond L. — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Grais Linda — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Hove Anders D — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | MITCHELL DANIEL J — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | CONWAY ROBERT E — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Flynn James P — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Funicular Funds, LP — 10% owner Ma-Weaver Jacob — Director, 10% owner | Option exercise/expiry (X): 1,420,000 @ $2.50 · Grant/award (A): 6,000 (derivative) @ $0 · Option exercise/expiry (X): 14,200 (derivative) @ $0 · Code (E): 300 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Woosley Raymond L. — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Grais Linda — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Hove Anders D — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | CONWAY ROBERT E — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | MITCHELL DANIEL J — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Dekker C. Jeffrey — Chief Financial Officer | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2022-12-09 | 4 | Keuer Thomas A — Chief Operating Officer | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2022-07-08 | 4 | Funicular Funds, LP — 10% owner | Other (J): 2,580,452 @ $0 · Other (J): 2,580,452 @ $0 · Other (J): 14,500 (derivative) @ $0 · Other (J): 14,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Ma-Weaver Jacob — Director, 10% owner | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-05-25 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 2,301 @ $2.29 · Purchase (P): 18,110 @ $2.29 · Purchase (P): 64,851 @ $2.32 | EDGAR |
| 2022-05-20 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 13,072 @ $2.30 · Purchase (P): 1 @ $2.25 | EDGAR |
| 2022-05-16 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 27,922 @ $2.27 · Purchase (P): 14,000 @ $2.29 · Purchase (P): 42,914 @ $2.30 | EDGAR |
| 2022-05-11 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 20,979 @ $2.28 · Purchase (P): 24,596 @ $2.29 | EDGAR |
| 2022-05-09 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 16,903 @ $2.27 · Purchase (P): 57,998 @ $2.28 · Purchase (P): 49,221 @ $2.27 | EDGAR |
| 2022-05-02 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 23,381 @ $2.32 · Purchase (P): 8,974 @ $2.30 · Purchase (P): 1,259 @ $2.31 | EDGAR |
| 2022-04-27 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 13,751 @ $2.29 · Sale (S): 7,500 (derivative) @ $64 | EDGAR |
| 2022-04-20 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 9,119 @ $2.31 · Sale (S): 7,000 (derivative) @ $64 | EDGAR |
| 2022-04-14 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 17,410 @ $2.33 | EDGAR |
| 2022-04-12 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 30,660 @ $2.31 · Purchase (P): 4,655 @ $2.31 · Purchase (P): 69,398 @ $2.32 | EDGAR |
| 2022-04-07 | 4 | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 49,728 @ $2.30 · Purchase (P): 26,806 @ $2.30 · Purchase (P): 27,450 @ $2.32 | EDGAR |
| 2022-04-07 | 4/A | Funicular Fund, LP Ma-Weaver Jacob | Purchase (P): 122,342 @ $2.26 | EDGAR |
| 2022-04-04 | 4 | Funicular Fund, LP | Purchase (P): 122,342 @ $2.26 | EDGAR |
| 2021-12-16 | 4 | Dekker C. Jeffrey — Chief Financial Officer | Grant/award (A): 17,700 (derivative) @ $0 | EDGAR |
| 2021-12-16 | 4 | Ozeroff Christopher David — S.V.P., General Counsel | Grant/award (A): 27,500 (derivative) @ $0 | EDGAR |
| 2021-12-16 | 4 | Keuer Thomas A — Chief Operating Officer | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2021-12-16 | 4 | BRISTOW MICHAEL R — Pres. & Chief Executive Offic, Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2021-11-23 | 4 | Ozeroff Christopher David — S.V.P., General Counsel | Purchase (P): 50,000 @ $2.26 | EDGAR |
| 2021-05-13 | 4 | CONWAY ROBERT E — Director | Purchase (P): 10,000 @ $3.19 | EDGAR |
| 2021-05-06 | 4 | CONWAY ROBERT E — Director | Purchase (P): 10,000 @ $3.23 | EDGAR |
| 2021-01-13 | 4 | Woosley Raymond L. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | Grais Linda — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | Hove Anders D — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | CONWAY ROBERT E — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | MITCHELL DANIEL J — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | Ozeroff Christopher David — S.V.P., General Counsel | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | Keuer Thomas A — Chief Operating Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | BRISTOW MICHAEL R — Pres. & Chief Executive Offic, Director | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — ARCA biopharma, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ABIO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs